Tocqueville Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Tocqueville Asset Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-45,500	Closed	-$402K	–	972
2015 Q3	$402K	Buy	45,500 +14,400	+46%	+$151K	0.01%	759
2015 Q2	$366K	Sell	31,100 -2,900	-9%	-$40.3K	﹤0.01%	792
2015 Q1	$492K	Buy	34,000 +15,000	+79%	+$230K	0.01%	720
2014 Q4	$324K	Sell	19,000 -3,500	-16%	-$50.5K	﹤0.01%	791
2014 Q3	$280K	Sell	22,500 -6,000	-21%	-$73.8K	﹤0.01%	751
2014 Q2	$418K	Sell	28,500 -1,000	-3%	-$15.3K	﹤0.01%	767
2014 Q1	$601K	Buy	29,500 +11,500	+64%	+$279K	0.01%	539
2013 Q4	$353K	Buy	18,000 +6,000	+50%	+$160K	﹤0.01%	667
2013 Q3	$544K	Sell	12,000 -6,200	-34%	-$202K	0.01%	622
2013 Q2	$434K	Buy	+18,200	New	+$290K	0.01%	668

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tocqueville Asset Management's STML Position: Q4 2015 in Review

Tocqueville Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q4 2015, closing a stake of 45,500 shares — an estimated $402K sold.

Tocqueville Asset Management first reported a position in STML in Q2 2013 and held it in 10 quarters. The position peaked at $601K in Q1 2014. 66 funds tracked by Wall St. Rank hold STML as of Q4 2015.

Tocqueville Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
Tocqueville Asset Management sold 45,500 Stemline Therapeutics, Inc. shares in Q4 2015, an estimated $402K.
Tocqueville Asset Management first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 10 quarters.
Tocqueville Asset Management's Stemline Therapeutics, Inc. position peaked at $601K in Q1 2014.
66 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2015.

Based on Tocqueville Asset Management's 13F filing for Q4 2015, filed 29 Jan 2016.